HB2375 expands Virginia’s prescription drug price transparency framework by requiring additional annual reporting from health carriers, pharmacy benefits managers (PBMs), and pharmacy services administrative organizations (PSAOs). The bill directs the Department of Health to contract with a nonprofit data services organization to collect, compile, and publish aggregated prescription drug pricing information on a public website, while protecting proprietary and confidential business information. It also updates definitions to include PSAOs and ties the reporting system to existing transparency laws covering carriers, PBMs, wholesale distributors, and manufacturers.
Under the bill, carriers must report data on the most frequently prescribed drugs, the highest-cost drugs, the drugs with the largest year-over-year cost increases, and certain premium and utilization-management metrics. PBMs must report rebate information, including rebates received, rebates passed through to health plans, and rebates passed on to enrollees at the point of sale. PSAOs must report negotiated reimbursement rates and fee schedules, unless they operate solely on flat service fees and do not base charges on drug prices or volume. The bill also authorizes civil penalties of up to $2,500 per day for failure to report required information, with authority for the Commissioner to reduce or waive penalties for good cause.
The bill’s impact on state law is to broaden and strengthen Virginia’s prescription drug transparency regime, creating a more detailed reporting structure and adding PSAOs as regulated reporting entities. It amends both the public health and insurance code provisions to coordinate reporting, confidentiality, and enforcement, and it requires regulations to be adopted for data collection, auditing, and penalty schedules. The bill also preserves confidentiality for submitted information except in aggregated public reports and exempts certain PSAOs from reporting if they only charge flat service fees.
The overall sentiment around HB2375 appears strongly supportive and noncontroversial. It advanced through committee and floor votes in both chambers unanimously or near-unanimously, including 22-0 in House committee, 97-0 in the House, 14-0 in Senate committee, and 40-0 in the Senate. That voting pattern suggests broad bipartisan agreement on increasing transparency in prescription drug pricing and pharmacy benefit arrangements.
The main points of contention, as reflected in the text rather than debate transcripts, are likely to involve the scope of reporting burdens, confidentiality protections, and the treatment of PSAOs. The bill balances transparency with limits on disclosure of specific plan, drug, rebate, and fee information, which may have been important to carriers, PBMs, manufacturers, and PSAOs. The exemption for PSAOs that only charge flat service fees also suggests some concern about avoiding unnecessary reporting for entities with simpler business models.
HB2375 amends Virginia Code §§ 32.1-23.4 and 38.2-3407.15:6 to expand prescription drug price transparency reporting and enforcement. It requires the Department of Health to use a nonprofit data services organization to collect and publish aggregated drug pricing data, adds PSAOs to the reporting framework, imposes civil penalties for noncompliance, and requires regulations for auditing and penalty schedules. It also preserves confidentiality for underlying submissions while allowing aggregated public disclosure.
The bill appears to have enjoyed broad bipartisan support and little visible opposition. It passed House and Senate votes unanimously or nearly unanimously, with committee and floor votes all recorded as 0 nays. That pattern indicates a generally favorable view of prescription drug transparency and the bill’s attempt to improve oversight without exposing proprietary information.
No committee transcript is available, so specific objections are not recorded. Based on the statutory language, the likely areas of concern are the administrative burden on carriers, PBMs, manufacturers, wholesale distributors, and PSAOs; the scope of confidential information protected from FOIA; and whether PSAOs should be subject to reporting at all. The bill addresses some of these concerns by limiting disclosure to aggregated data, allowing penalty waivers for good cause, and exempting PSAOs that only charge flat service fees.